Clinical Trials
7 trialsNCT07071961 2026-06-05
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT07619937 2026-06-02
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT02693535 2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT04503694 2026-05-22
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT04787341 2026-05-20
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT06246643 2026-05-19
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
Phase 2 Active not recruiting